Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Mol Cancer Ther. 2018 Feb 26;17(5):885–896. doi: 10.1158/1535-7163.MCT-17-0758

Figure 3. Osimertinib and AZ5104 monotherapy induce tumor growth inhibition in both NSCLC H2073 Ex20Ins SVD and ASV xenograft models in vivo.

Figure 3

Tumor growth inhibition following daily dosing of vehicle, osimertinib 25 mg/kg once daily, AZ5104 50 mg/kg once daily or afatinib 7.5 or 20 mg/kg once daily in the subcutaneous, (A) H2073-SVD or (B) H2073-ASV, xenograft model in CB17 SCID mice. (C) and (D) No significant body weight loss (less than 10% of starting body weight) is observed at these efficacious doses. Data expressed as percentage change in CB17 SCID mouse body weight relative to start size on day 0.

Data are represented as mean ± SEM (n=10 for vehicle and n=5 for osimertinib, AZ5104 and afatinib treated groups.